Logo image
Back
COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA
Journal article   Peer reviewed

COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA

M.S. Krantz and E.J. Phillips
The Lancet Infectious Diseases, Vol.22(6), pp.P747-748
2022
DOI: https://doi.org/10.1016/S1473-3099(22)00123-2
url
Link to Published Version *Subscription may be requiredView

Abstract

A primary mission of the US vaccination campaign, which began in December, 2020, following emergency use authorisation (EUA) of the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 mRNA vaccines, was ensure vaccine benefit while monitoring vaccine safety.(1, 2) This mission was facilitated by both the enormity of the roll-out and mRNA COVID-19 vaccine distribution and the administration by the US Government of all doses, giving an unprecedented opportunity to measure vaccine safety. As of Feb 28, 2022, over 530 million doses of mRNA COVID-19 vaccines had been administered in the USA. In The Lancet Infectious Diseases, Hannah Rosenblum and colleagues (3) from the US Centers for Disease Control and Prevention report the first 6 months (Dec 14, 2020, to June 14, 2021) of safety monitoring of mRNA COVID-19 vaccines, in individuals aged at least 16 years, during which time over 50% of the eligible US population received at least one vaccine dose and more than 298 million doses were administered.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

30 Record Views
5 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.104 Virology - General
1.104.1353 Coronavirus Research
Web Of Science research areas
Infectious Diseases
ESI research areas
Immunology
Logo image